Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
DANIELA Poenaru
 -- 2837 2023-07-11 17:41:59 |
2 Reference format revised.
Lindsay Dong
Meta information modification 2837 2023-07-13 02:51:23 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Poenaru, D.; Sandulescu, M.I.; Cinteza, D. Chronic Musculoskeletal Disorders Pain Management by Botulinum Toxin. Encyclopedia. Available online: https://encyclopedia.pub/entry/46655 (accessed on 27 July 2024).
Poenaru D, Sandulescu MI, Cinteza D. Chronic Musculoskeletal Disorders Pain Management by Botulinum Toxin. Encyclopedia. Available at: https://encyclopedia.pub/entry/46655. Accessed July 27, 2024.
Poenaru, Daniela, Miruna Ioana Sandulescu, Delia Cinteza. "Chronic Musculoskeletal Disorders Pain Management by Botulinum Toxin" Encyclopedia, https://encyclopedia.pub/entry/46655 (accessed July 27, 2024).
Poenaru, D., Sandulescu, M.I., & Cinteza, D. (2023, July 11). Chronic Musculoskeletal Disorders Pain Management by Botulinum Toxin. In Encyclopedia. https://encyclopedia.pub/entry/46655
Poenaru, Daniela, et al. "Chronic Musculoskeletal Disorders Pain Management by Botulinum Toxin." Encyclopedia. Web. 11 July, 2023.
Chronic Musculoskeletal Disorders Pain Management by Botulinum Toxin
Edit
This entry is adapted from the peer-reviewed paper 10.3390/biomedicines11071888

Botulinum neurotoxin (BoNT), a product of Clostridium botulinum, reversibly inhibits the presynaptic release of the neurotransmitter acetylcholine at the neuromuscular junction. In addition, BoNT blocks the transmission of other substances involved in pain perception and, together with a soft-tissue anti-inflammatory effect, may play a role in analgesia. When first-line treatment fails, second-line therapies might include BoNT. Studies on chronic and recurrent pain using different mechanisms offer heterogenous results that must be validated and standardized. Plantar fasciitis, severe knee osteoarthritis, painful knee and hip arthroplasty, antalgic muscular contractures, and neuropathic and myofascial pain syndromes may benefit from the administration of BoNT. 

botulinum neurotoxin neuropathic pain musculoskeletal disorders

1. Introduction

Botulinum neurotoxin (BoNT) is a product of Clostridium botulinum. BoNT acts on specific proteins, SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptors), which mediate neuronal exocytosis and reversibly inhibit the presynaptic release of neurotransmitters at the neuromuscular junction, with acetylcholine and substance P (a neuropeptide acting as a neurotransmitter and a modulator of pain perception) being primarily affected. Acetylcholine reduction causes muscular weakness and substance P reduction is responsible for analgesia [1].
There are seven BoNT serotypes, termed A to G. Each serotype cleaves one of the SNARE proteins (soluble N-ethylmaleimide-sensitive factor attachment protein receptors). BoNT serotypes A and B have been approved for pharmacological use. BoNT/A has three formulations: onabotulinumtoxin A (Botox, Allergan), abobotulinumtoxin A (Dysport, Medicis), and incobotulinumtoxin A (Xeomin, Merz). Serotype B is available under the name rimabotulinumtoxin B (Myobloc, Neurobloc) [2]. The equivalence between BoNT/A and BoNT/B ranges from 1:40 to 1:67 UI.
Generally, the main indications of BoNT are focal dystonia, spasticity (upper motor neuron lesion), non-dystonic disorders of involuntary muscle activity, strabismus, smooth muscle hyperactive disorders, sweating and salivary disorders, and cosmetic use.
Chronic pain syndromes with recurrent or refractory courses are difficult to manage and are the subjects of extensive research. BoNT may have a place in the treatment of some diseases, mainly when more conventional therapies fail (See Table 1, Figure 1).
/media/item_content/202307/64af49a5de15cbiomedicines-11-01888-g001.png
Figure 1. Proposed BoNT mechanisms.
Table 1. Main BoNT indications of analgesia.
Disease Administration Number of Studies
Plantar fasciitis Intrafascial
Intramuscular (short plantar muscles)
Intramuscular (medial head gastrocnemius)		 10
Knee osteoarthritis Intra-articular 6
Painful knee arthroplasty Intra-articular
Intramuscular (for contractures)		 3
Painful muscular contractures Intramuscular 3
Chronic lateral epicondylitis Intratendinous
Intramuscular		 6
Neuropathic pain Intradermal, subcutaneous/submucosal
Perinervous
Sympathetic block		 16
Carpal tunnel syndrome Intracannalar
Intramuscular		 1
Morton neuroma Perineural 1
Myofascial pain syndrome Trigger point injection 6

2. Chronic Musculoskeletal Disorders Pain Management by Botulinum Toxin 

2.1. Plantar Fasciitis

Plantar fasciitis often has a chronic evolution, with recurrences or treatment refractoriness. The last therapeutic resort is surgery, with debridement and release of fascia. Trying to avoid the shortcomings of surgery has raised interest in new therapeutic agents such as BoNT [3].
Heel pain is usually caused by plantar fasciitis, although this may not always be the case. Neuropathic conditions such as entrapment of the posterior tibialis nerve, inferior calcaneal nerve, medial plantar nerve, and lateral plantar nerve may mimic or be associated with plantar fasciitis. Quadratus plantae and abductor hallucis brevis muscles exert pressure on and entrap the above-mentioned nerves [4].
Intrafascial injection techniques vary based on different studies. Babcock used two doses of intrafascial injection of 70 UI BoNT/A (Botox; Allergan, Irvine, CA, USA) under palpatory guidance: 40 UI in the tender region of the heel medial to the insertion of fascia and 30 UI in the tender point of the arch of the foot (one inch distal to the talar insertion of fascia) [5]. Using this technique, two articles reported significant improvement in pain and function, both in the short-term (3 and 8 weeks) and the long-term (6 and 12 months) [5][6]. Plantar fascia thickness decreased on ultrasound examination at 1 and 3 weeks and was correlated with clinical improvement [7]. Comparing this regimen with local corticosteroids and anaesthetics showed that both treatments reduced pain at one month; however, botulinum toxin was superior at 6 and 12 months, with a remanent effect long after termination of direct pharmacological action [8]. Another injection technique used a dose of 200 UI BoNT/A (Dysport, Ipsen Pharma, Ettlingen, Germany), equivalent to 30–40 UI Botox), administered into the most tender point via plantar approach and into the subfascial area in four different directions, producing pain relief and pressure pain threshold reduction at 2 weeks that was maintained for up to 52 weeks. However, researchers found no significant difference when it was compared with the placebo [8][9]. Ultrasound-guided injection of 50 UI botulinum toxin A into the fascia with a posterior approach below the calcaneus reduced pain at three months. Additionally, the ultrasound also validated a reduction in fascia thickness [10].
Intramuscular injections were administered into the flexor digitorum brevis, abductor hallucis, quadratus plantae, and medial gastrocnemius muscles.
Intramuscular injection of 100 UI incobotulinumtoxin A (Xeomin, Merz) into the flexor digitorum brevis muscle in the proximity of plantar fascia with electromyographic validation produced significant pain and reduced dysfunction [11]. Intramuscular injection (abductor hallucis brevis, 50 UI; quadratus plantae, 50 UI Dysport) under EMG guidance with subsequent paralysis of these muscles and decompression of nervous branches relieved pain and improved function during daily activities. Supplementary analgesia may result from the toxin’s diffusion to the plantar medial heel, with direct neuron-analgesic and musculoskeletal anti-inflammatory effects [12].

2.2. Knee Osteoarthritis

There is currently no cure or ability to reverse the degenerative process; the main objective of any treatment should be alleviating pain, decreasing inflammation, restoring function, and decelerating the progression of the disease. Pain modulation for maintaining function when intra-articular corticosteroids and other first- and second-line therapies have failed or are not indicated may benefit from BoNT administration. Its analgesic and anti-inflammatory properties are due to the inhibition of the release of some neurotransmitters from nerve terminals, including substance P, calcitonin gene-related peptide (CGRP), and neurokinin A [13].
Research on treating different grades of knee osteoarthritis (II, III, and IV Kelgren-Lawrence stage [13]) with intraarticular injections of 100 UI BoNT/A (Botox) or 250 UI BoNT/A (Dysport) reported pain and functional improvement lasting from one week to six months. A second identical injection administered after three months may act as a booster, leading to the assumption that the therapeutic result is transient rather than long-term [14][15][16].
The results for moderate chronic knee osteoarthritis are heterogeneous. Comparing intra-articular doses of 100 UI BoNT/A and 200 UI BoNT/A combined with corticosteroids decreased pain in every group at 8 weeks, with even low-dose BoNT/A reaching statistical significance [17]. In another study, 100 UI BoNT/A had no effect on pain and function, either in the short-term or the medium-term [18].
Intra-articular botulinum toxin was safe, with no adverse effects. In intramuscular administration, adverse reactions were rare and, when they occurred, were mild and transient, including local pain and clinical signs of toxin diffusion into the adjacent tissue (dysphagia following neck muscle injection; diplopia or ptosis following orbicularis oculi injection; skin rash, dizziness, generalized fatigue, dry mouth, reduced sweating, and constipation). Studies on intra-articular administration revealed none of the above-mentioned reactions [14][15][19].

2.3. Painful Knee Arthroplasty

Painful knee arthroplasty is a challenge, since after the exclusion of infection, loosening, and instability, medical or surgical alternatives are scarce. In this situation, intra-articular administration of 100 UI BoNT/A (Botox) reduced pain and improved function after 2 months, strengthening its short-term analgesic effect. With an average of 39 days of pain relief, there was a need for a second injection or a higher dose to sustain the analgesic effect for a longer duration [20]. The researchers administered a second and third dose of botulinum toxin (100–300 UI) in cases where pain recurred or responses failed.

2.4. Joint Contractures

Postoperative knee flexion contracture occurs in 15–20% of patients and has important biomechanical consequences. Most studies recommend botulinum toxin for muscle spasticity, i.e., upper motor neuron lesions. In the case of knee arthroplasty, hamstring tightness is secondary to local causes. After palpation of the most tender point of the medial and lateral hamstring muscle bellies, 50 UI botulinum toxin was injected into each point and the patient was assigned a program of physical therapy. One month later, the knee’s range of motion improved and results were maintained for one year. The injection reduced muscular tightness and allowed the patient to attempt rehabilitation to achieve the correct range of motion [21].
Moderate-to-severe flexion contractures (greater than 15°) require surgical intervention—one of the many therapeutic procedures conducted under anaesthesia. Peroneal nerve decompression, posterior soft tissue release (capsule and tendons), and botulinum toxin injection (150–200 UI) into the gastrocnemius and hamstrings can be efficacious treatments with complete correction of the deformity. Botulinum toxin has been proven to be a valuable tool for improving the alignment and consequent disability [22].
Knee flexion contracture is a frequent complication in children and young adult haemophilic patients. Acute joint distension and pain block quadriceps function and create a muscular imbalance in favour of knee flexors. Muscle haematoma and advanced knee arthropathy are associated with flexor contracture due to limited mobility or severe internal joint damage [23]. When a 6-month rehabilitation program fails to restore knee extension, intramuscular botulinum toxin administration may be considered, especially for knee contractures between 10° and 30°, usually secondary to hemarthrosis with inadequate replacement therapy. For knee contractures ranging from 31° to 45° and with muscle imbalance, intramuscular toxin administration may precede hamstring release. There were no benefits for flexion contractures above 45°. A total dose of 100 UI BoNT/A was injected into the hamstrings, fascia lata, and calf muscles under factor replacement protection [23].
In the same manner, a small proportion of patients with total hip arthroplasty develop hip contractures, limiting the range of motion and, ultimately, the gait and quality of life. The most frequently involved muscles are adductors, tensor fascia lata, and rectus femoris [24]. Various attempts have been made to limit these contractures—including surgical techniques associated with rehabilitation programs—with the rate of success varying between 0 and 60% [25]. Researchers proposed intramuscular administration of 100 UI into the adductor magnus and brevis, rectus femoris, and tensor fascia lata, based on clinical examination. After this procedure, the patients started a rehabilitation regimen. At the one-year follow-up visit, gain of hip mobility was on average 23° for those with restricted movement, with full extension to standing [26].

2.5. Chronic Lateral Epicondylitis

Chronic lateral epicondylitis, a degenerative inflammatory disorder, may follow a chronic or recurrent course. The rationale behind recommending botulinum toxin is supported by two mechanisms: a paralysing effect on extensor muscles that reduces tension in their tendons (protection) and an analgesic effect due to inhibition of the neurotransmitters involved in pain transmission [1].
BoNT/A, tested in doses varying from 40 to 60 UI via unique injections, provided significant improvement in visual analogue scale (VAS) pain assessment at week 4 that persisted to week 12 and led to no or minimal alteration in grip strength. The administration site varied across studies (intratendinous or intramuscular). Intratendinous administration site was 1 cm distal to the lateral epicondyle toward the tender spot [27]. Intramuscular administration varied between studies: 3 to 4 cm distal to the lateral epicondyle with infiltration of the muscle at two locations [28], 5 cm distal to the area of maximal tenderness at the lateral epicondyle, in line with the middle of the wrist [29], or at the site where the motor nerve branch (posterior interosseous nerve) enters the extensor digitorum and extensor carpi ulnaris muscles. This point is at a distance of 33% of the forearm length from the lateral epicondyle to the posterior midpoint of the wrist [30].
Intramuscular administration of low doses of botulinum toxin into the extensor carpi radialis brevis muscle under electromyographic guidance was confirmed to have an analgesic effect at 30 and 90 days and spared the extensor digitorum muscle, avoiding the extensor lag with no interference to daily and work activities. Thus, it seems that targeting the right muscle using a low dose may induce short-term pain reduction and functional improvement [31].
The role of botulinum toxin in the therapeutic armamentarium of lateral epicondylitis has to be defined, as researchers have documented an equivalent effect, in terms of pain relief, using corticosteroids. It is worth mentioning that corticosteroids provide analgesia in the early stages while the analgesic effect of botulinum toxin could last for 16 weeks. Recurrence rate and risks of corticosteroid injections are important issues to consider [32]. On the other hand, adverse effects of botulinum toxin, including local paresthesia, ecchymosis, and skin irritation, need to be mentioned. The high costs of this product should also be considered [33].

2.6. Neuropathic Pain

Focal postherpetic and post-traumatic pain, diabetic neuropathy, complex regional pain syndrome, and trigeminal neuralgia are subjects of scientific research.
Focal postherpetic and post-traumatic pain with mapping of the precise area of allodynia and intradermal injection of 200 UI BoNT/A (Botox) following the hyperhidrosis scheme were followed by a reduction in the intensity and the area of pain, as well as a decrease in cold and pain thresholds, although perception thresholds remained constant [34]. First-line trigeminal neuralgia treatment is represented by carbamezepine and oxcarbazepine, with good efficacy; their clinical benefit may diminish over time and side effects may be severe.
One injection provided a significant analgesic effect. For patients unresponsive to one injection, repeating the procedure after 2 weeks led to better control of pain, with no increase in the number of side reactions. Regarding the total dose per area, research suggests that low doses (25–40 UI) and high doses (75–100 UI) have similar effects in the short term, whereas high doses have a better effect in the long term, with no additional adverse reactions [35][36].
Injecting the maxillary and mandibular roots with 50 UI botulinum toxin (Botox) offered statistical and clinical improvement in pain intensity and attack frequency, beginning in the first week and persisting for six months. However, about half of the 27 patients experienced recurrence and asked for a second injection [37].
Intradermal injections may be painful, thus local anaesthesia with topical lidocaine or prilocaine was provided; some researchers added inhalatory nitrous oxide 5 min before and throughout the procedure [37].
Botulinum toxin certainly has a place in postherpetic and trigeminal neuralgia, with some researchers raising the question of whether it should remain a second-line treatment or become a first-line treatment, given its efficacy and tolerability [38].
Peripheral diabetic neuropathy is a symmetrical distal sensory and motor polyneuropathy with a wide spectrum of therapeutic agents, such as antidepressants, anticonvulsants, and opioids. They are reported to lack long-lasting pain relief, and to carry poor tolerability and disturbing side effects. Topical lidocaine and capsaicine (high dose) or botulinum toxin have been studied as alternatives [39].
A total of 100 UI BoNT/A injected intradermally into the dorsal foot in a grid distribution pattern provided analgesia beginning on the first week and maintained for up to three months with no side effects [40][41]. Based on the small number of studies on peripheral diabetic neuropathy with particular localization to the dorsum of the foot, botulinum toxin may act as an adjunctive treatment to first-line modalities.

2.7. Carpal Tunnel Syndrome

Cases of mild and moderate severity were treated with 30 UI botulinum toxin A under sonographic intracanal guidance to obtain a reduction in paraesthesia and nocturnal pain [42].
Another study used intramuscular administration of botulinum toxin into the motor points of flexor digitorum profundis (10 UI), flexor digitorum superficialis (10 UI), and flexor pollicis longus (5 UI) to reduce tension in the tendons travelling to the carpal tunnel and, consequently, the pressure on the median nerve. Results showed significant clinical improvement as well as distal motor latencies and sensor nerve conduction velocity improvements after 12 weeks [43].

2.8. Morton Neuroma

Patients with Morton’s neuroma who experienced long-lasting pain and failure of conservative therapies, including corticosteroid injections, received 50 UI botulinum toxin A in the area of the neuroma (identified on MRI exam), with 70% of patients reporting pain relief and foot function improvement at one-month and three-month follow-ups. Researchers noticed that the results at 3 months were better than at 1 month, in contrast to the evolution of the antispastic effect, which peaked at 1–3 weeks, was followed by a plateau for 1–2 months, and needed re-injection every 3 months [44].

2.9. Myofascial Pain Syndrome

The pathophysiology of myofascial pain syndrome is unclear, as it plays the role of muscular contracture in pain generation. Many therapeutic approaches have been suggested, including local injections with anaesthetics, saline, corticosteroids, or dry-needling—with varying results. Adjunctive physiotherapy is critical for maximizing the pharmacological strategy [45].
For upper back and shoulder myofascial pain syndrome occurring over a long duration (at least 6 months), palpatory identification and injection of botulinum toxin to accessible trigger points (with doses of 10–20–40 UI per point) produced significant analgesic effect and reduced fatigue and work disability at 4 weeks. Smaller doses of 5 UI per trigger point, with a total number of 3–7 trigger points per patient, offered no advantage compared with simple saline injections. Other researchers found equal analgesic effects of botulinum toxin and local anaesthetics injected directly into the trigger points. Thus, treatment should be reserved for patients who fail to respond to other injectable therapies, mainly due to the higher cost of this pharmaceutical [46][47][48][49].

3. Conclusions

Chronic or recurrent pain due to a variety of musculoskeletal disorders is a complex syndrome with incompletely known mechanisms and a variety of therapeutic approaches and success rates. In many cases, first-line treatments are well-defined, whereas their failure presents the physician and patient with a large range of therapies with heterogeneous studies and results. Botulinum neurotoxin plays a role in chronic pain management based on its nociceptive neurotransmitter blockage and anti-inflammatory effect. Dosing and timing of BoNT administration in chronic or refractory cases of plantar fasciitis and other tendinopathies, knee osteoarthritis and arthroplasty, and joint contractures and neuropathic pain are subjects of thorough and promising research.

References

  1. Lew, M.F. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin. J. Pain 2002, 18 (Suppl. S6), S142–S146.
  2. Chen, S. Clinical uses of botulinum neurotoxins: Current indications, limitations and future developments. Toxins 2012, 4, 913–939.
  3. Wheeler, P.; Boyd, K.; Shipton, M. Surgery for patients with recalcitrant plantar fasciitis: Good results at short-, medium-, and long-term follow-up. Orthop. J. Sports Med. 2014, 2, 2325967114527901.
  4. Neufeld, S.K.; Cerrato, R. Plantar fasciitis: Evaluation and treatment. J. Am. Acad. Orthop. Surg. 2008, 16, 338–346.
  5. Díaz-Llopis, I.V.; Gómez-Gallego, D.; Mondéjar-Gómez, F.J.; López-García, A.; Climent-Barberá, J.M.; Rodríguez-Ruiz, C.M. Botulinum toxin type A in chronic plantar fasciitis: Clinical effects one year after injection. Clin. Rehabil. 2013, 27, 681–685.
  6. Babcock, M.S.; Foster, L.; Pasquina, P.; Jabbari, B. Treatment of pain attributed to plantar fasciitis with botulinum toxin A: A short-term, randomized, placebo-controlled, doubleblind study. Am. J. Phys. Med. Rehabil. 2005, 84, 649–654.
  7. Chou, L.W.; Hong, C.Z.; Wu, E.S.; Hsueh, W.H.; Kao, M.J. Serial Ultrasonographic Findings of Plantar Fasciitis After Treatment with Botulinum Toxin A: A Case Study. Arch. Phys. Med. Rehabil. 2011, 92, 316–319.
  8. Placzek, R.; Deuretzbacher, G.; Buttgereit, F.; Meiss, A.L. Treatment of chronic plantar fasciitis with botulinum toxin A: An open case series with a 1 year follow up. Ann. Rheum. Dis. 2005, 64, 1659–1661.
  9. Peterlein, C.D.; Funk, J.F.; Hölscher, A.; Schuh, A.; Placzek, R. Is Botulinum Toxin An Effective for the Treatment of Plantar Fasciitis? Clin. J. Pain 2012, 28, 527–533.
  10. Elizondo-Rodríguez, J.; Simental-Mendía, M.; Peña-Martínez, V.; Vilchez-Cavazos, F.; Tamez-Mata, Y.; Acosta-Olivo, C. Comparison of Botulinum Toxin A, Corticosteroid, and Anesthetic Injection for Plantar Fasciitis. Foot Ankle Int. 2021, 42, 305–313.
  11. Ahmad, J.; Ahmad, S.H.; Jones, K. Treatment of Plantar Fasciitis with Botulinum Toxin. Foot Ankle Int. 2017, 38, 1–7.
  12. Radovic, P. Treatment of “Plantar Fasciitis”/Plantar Heel Pain Syndrome with Botulinum Toxin- A Novel Injection Paradigm Pilot Study. Foot 2020, 45, 101711.
  13. Fonfria, E.; Maignel, J.; Lezmi, S.; Martin, V.; Splevins, A.; Shubber, S.; Kalinichev, M.; Foster, K.; Picaut, P.; Krupp, J. The Expanding Therapeutic Utility of Botulinum Neurotoxins. Toxins 2018, 10, 208.
  14. Kellgren, J.; Lawrence, J. Radiological assessment of osteoarthrosis. Ann. Rheum. Dis. 1957, 16, 494–502.
  15. Chou, C.L.; Lee, S.H.; Lu, S.Y.; Tsai, K.L.; Ho, C.Y.; Lai, H.C. Therapeutic effects of intra-articular botulinum neurotoxin in advanced knee osteoarthritis. J. Chin. Med. Assoc. 2010, 73, 573–580.
  16. Hsieh, L.F.; Wu, C.W.; Chou, C.C.; Yang, S.W.; Wu, S.H.; Lin, Y.J.; Hsu, W.C. Effects of Botulinum Toxin Landmark-Guided Intra-articular Injection in Subjects With Knee Osteoarthritis. PM R J. Inj. Funct. Rehabil. 2016, 8, 1127–1135.
  17. Najafi, S.; Sanati, E.; Khademi, M.; Abdorrazaghi, F.; Mofrad, R.K.; Rezasoltani, Z. Intra-articular botulinum toxin type A for treatment of knee osteoarthritis: Clinical trial. Toxicon 2019, 165, 69–77.
  18. Mendes, J.G.; Natour, J.; Nunes-Tamashiro, J.C.; Toffolo, S.R.; Rosenfeld, A.; Furtado, R.N.V. Comparison between intra-articular Botulinum toxin type A, corticosteroid, and saline in knee osteoarthritis: A randomized controlled trial. Clin. Rehabil. 2019, 33, 1015–1026.
  19. Zhai, S.; Huang, B.; Yu, K. The efficacy and safety of Botulinum Toxin Type A in painful knee osteoarthritis: A systematic review and meta-analysis. J. Int. Med. Res. 2020, 48, 300060519895868.
  20. Sun, S.F.; Hsu, C.W.; Lin, H.S.; Chou, Y.J.; Chen, J.Y.; Wang, J.L. Efficacy of intraarticular botulinum toxin A and intraarticular hyaluronate plus rehabilitation exercise in patients with unilateral ankle osteoarthritis: A randomized controlled trial. J. Foot Ankle Res. 2014, 7, 9.
  21. Singh, J.A.; Mahowald, M.L.; Noorbaloochi, S. Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: A randomized controlled trial. J. Rheumatol. 2010, 37, 2377–2386, Erratum in J. Rheumatol. 2011, 38, 1534.
  22. Singh, J.A. Efficacy of Long-term Effect and Repeat Intraarticular Botulinum toxin in Patients with Painful Total Joint Arthroplasty: A Retrospective Study. Br. J. Med. Med. Res. 2014, 4, 139–148.
  23. Vahedi, H.; Khlopas, A.; Szymczuk, V.L.; Peterson, M.K.; Hammouda, A.I.; Conway, J.D. Treatment with posterior capsular release, botulinum toxin injection, hamstring tenotomy, and peroneal nerve decompression improves flexion contracture after total knee arthroplasty: Minimum 2-year follow-up. Knee Surg. Sports Traumatol. Arthrosc. 2020, 28, 2706–2714.
  24. Knobe, K.; Berntorp, E. Haemophilia and joint disease: Pathophysiology, evaluation, and management. J. Comorb. 2011, 1, 51–59.
  25. Daffunchio, C.; Caviglia, H.; Nassif, J.; Morettil, N.; Galatro, G. Knee flexion contracture treated with botulinum toxin type A in patients with haemophilia (PWH). Haemophilia 2015, 22, 134–141.
  26. Berend, M.E.; Smith, A.; Meding, J.B.; Ritter, M.A.; Lynch, T.; Davis, K. Long-term outcome and risk factors of proximal femoral fracture in uncemented and cemented total hip arthroplasty in 2551 hips. J. Arthroplast. 2006, 21, 53.
  27. Bhave, A.; Marker, D.R.; Seyler, T.M.; Ulrich, S.D.; Plate, J.F.; Mont, M.A. Functional problems and treatment solutions after total hip arthroplasty. J. Arthroplast. 2007, 22, 116–124.
  28. Bhave, A.; Zywiel, M.G.; Ulrich, S.D.; McGrath, M.S.; Seyler, T.M.; Marker, D.R.; Delanois, R.E.; Mont, M.A. Botulinum toxin type A injections for the management of muscle tightness following total hip arthroplasty: A case series. J. Orthop. Surg. Res. 2009, 4, 34.
  29. Wong, S.M.; Hui, A.C.F.; Tong, P.Y.; Poon, D.W.F.; Yu, E.; Wong, L.K.S. Treatment of Lateral Epicondylitis with Botulinum Toxin. Ann. Intern. Med. 2005, 143, 793.
  30. Placzek, R.; Drescher, W.; Deuretzbacher, G.; Hempfing, A.; Meiss, A.L. Treatment of Chronic Radial Epicondylitis with Botulinum Toxin A. J. Bone Jt. Surg. 2007, 89, 255–260.
  31. Hayton, M.J.; Santini, A.J.A.; Hughes, P.J.; Frostick, S.P.; Trail, I.A.; Stanley, J.K. Botulinum Toxin Injection in the Treatment of Tennis Elbow. J. Bone Jt. Surg. 2005, 87, 503–507.
  32. Creuzé, A.; Petit, H.; de Sèze, M. Short-Term Effect of Low-Dose, Electromyography-Guided Botulinum Toxin A Injection in the Treatment of Chronic Lateral Epicondylar Tendinopathy: A Randomized, Double-Blinded Study. J. Bone Jt. Surg. Am. 2018, 100, 818–826.
  33. Cogné, M.; Creuzé, A.; Petit, H.; Delleci, C.; Dehail, P.; de Seze, M. Number of botulinum toxin injections needed to stop requests for treatment for chronic lateral epicondylar tendinopathy. A 1-year follow-up study. Ann. Phys. Rehabil. Med. 2019, 62, 336–341.
  34. Lin, Y.C.; Wu, W.T.; Hsu, Y.C.; Han, D.S.; Chang, K.V. Comparative effectiveness of botulinum toxin versus non-surgical treatments for treating lateral epicondylitis: A systematic review and meta-analysis. Clin. Rehabil. 2017, 32, 131–145.
  35. Wu, S.; Lian, Y.; Zhang, H.; Chen, Y.; Wu, C.; Li, S.; Zheng, Y.; Wang, Y.; Cheng, W.; Huang, Z. Botulinum Toxin Type A for refractory trigeminal neuralgia in older patients: A better therapeutic effect. J. Pain Res. 2019, 12, 2177–2186.
  36. Zúñiga, C.; Piedimonte, F.; Díaz, S.; Micheli, F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin. Neuropharmacol. 2013, 36, 146–150.
  37. Zhang, H.; Lian, Y.; Ma, Y.; Chen, Y.; He, C.; Xie, N.; Wu, C. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: Observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J. Headache Pain 2014, 15, 65.
  38. Xiao, L.; Mackey, S.; Hui, H.; Xong, D.; Zhang, Q.; Zhang, D. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med. 2010, 11, 1827–1833.
  39. Apalla, Z.; Sotiriou, E.; Lallas, A.; Lazaridou, E.; Ioannides, D. Botulinum Toxin A in Postherpetic Neuralgia. Clin. J. Pain 2013, 29, 857–864.
  40. Shackleton, T.; Ram, S.; Black, M.; Ryder, J.; Clark, G.T.; Enciso, R. The efficacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: A systematic review with meta-analyses. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2016, 122, 61–71.
  41. Finnerup, N.B.; Sindrup, S.H.; Jensen, T.S. Recent advances in pharmacological treatment of neuropathic pain. F1000 Med. Rep. 2010, 2, 52.
  42. Lee, Y.; Lee, C.J.; Choi, E.; Lee, P.B.; Lee, H.J.; Nahm, F.S. Lumbar Sympathetic Block with Botulinum Toxin Type A and Type B for the Complex Regional Pain Syndrome. Toxins 2018, 10, 164.
  43. Tsai, C.P.; Liu, C.Y.; Lin, K.P.; Wang, K.C. Efficacy of botulinum toxin type a in the relief of Carpal tunnel syndrome: A preliminary experience. Clin. Drug Investig. 2006, 26, 511–515.
  44. Hablas, S.A.; Nada, D.W.; Alashkar, D.S.; Elsharkawy, A.A. The effect of botulinum toxin type A injection in decreasing intratunnel tendon tension in carpal tunnel syndrome: A randomized controlled trial for efficacy and safety. Egypt. Rheumatol. Rehabil. 2019, 46, 299–303.
  45. Climent, J.M.; Mondéjar-Gómez, F.; Rodríguez-Ruiz, C.; Díaz-Llopis, I.; Gómez-Gallego, D.; Martín-Medina, P. Treatment of Morton Neuroma with Botulinum Toxin A: A Pilot Study. Clin. Drug Investig. 2013, 33, 497–503.
  46. Ojala, T.; Arokoski, J.P.A.; Partanen, J. The Effect of Small Doses of Botulinum Toxin A on Neck-Shoulder Myofascial Pain Syndrome: A Double-Blind, Randomized, and Controlled Crossover Trial. Clin. J. Pain 2006, 22, 90–96.
  47. Kamanli, A.; Kaya, A.; Ardicoglu, O.; Ozgocmen, S.; Zengin, F.O.; Bayık, Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol. Int. 2004, 25, 604–611.
  48. Göbel, H.; Heinze, A.; Reichel, G.; Hefter, H.; Benecke, R. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport®) for the relief of upper back myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicentre study. Pain 2006, 125, 82–88.
  49. Graboski, C.L.; Gray, S.D.; Burnham, R.S. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind crossover study. Pain 2005, 118, 170–175.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Rheumatology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Daniela Poenaru
,
Miruna Ioana Sandulescu
,
Delia Cinteza
View Times: 297
Revisions: 2 times (View History)
Update Date: 13 Jul 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback